Dr. Ruizeng Dong 董锐增
Chief Physician
Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis, comprehensive care, and individualized treatment for abdominal tumors, including those of the liver, gallbladder, pancreas, and gastrointestinal tract.
Dr. Dong earned a clinical medicine degree from Shanghai Medical University in 1998, followed by a master’s (2004) and doctorate (2009) in surgical oncology from Fudan University Shanghai Cancer Center. Since 2009, Dr. Dong has worked at Zhejiang Cancer Hospital, focusing on clinical and basic research for abdominal tumors. Dr. Dong has led or participated in three provincial-level projects and published over 20 professional papers.
Name order: in Chinese the family name comes first (Dong Ruizeng). Papers usually list the name as Ruizeng Dong or Dong R.
Selected publications
11 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochem Biophys Res Commun, 2018 (first author): Polyphyllin I inhibits gastric cancer cell proliferation by downregulating the expression of fibroblast activation protein alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated fibroblasts. PubMed 29499193
- Zhonghua Wei Chang Wai Ke Za Zhi, 2018 (first author): [Surgical treatment and prognosis of Borrmann type IIII( gastric cancer involving the whole stomach]. PubMed 29492918
- Oncotarget, 2017 (first author): Prognostic impact and implications of extracapsular lymph node spread in Borrmann type IV gastric cancer. PubMed 29228635
- World J Surg Oncol, 2014 (senior author): Expression of multidrug resistance-associated proteins and their relation to postoperative individualized chemotherapy in gastric cancer. PubMed 25304659
- Med Hypotheses, 2013 (senior author): TAK-242 can be the potential agents for preventing invasion and metastasis of hepatocellular carcinoma. PubMed 23910073
- Chin J Cancer Res, 2013 (senior author): D2 plus radical resection combined with perioperative chemotherapy for advanced gastric cancer with pyloric obstruction. PubMed 23997543
- Chin J Cancer Res, 2013 (senior author): Laparoscopic-assisted radical gastrectomy for distal gastric cancer. PubMed 23997536
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion